Grown Rogue International (GRUSF) Net Income towards Common Stockholders (2009 - 2026)
Grown Rogue International (GRUSF) posted quarterly Net Income towards Common Stockholders of -$99657.0 for Q1 2026, up 100.0% quarter-over-quarter from -$6493.3 billion in Q4 2025.
Grown Rogue International (GRUSF) Net Income towards Common Stockholders (2009 - 2026) Analysis & Trends
Grown Rogue International's Net Income towards Common Stockholders history runs 18 years deep, the most recent figure standing at -$99657.0 for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders changed N/A year-over-year to -$99657.0; the TTM figure through Mar 2026 stood at -$3795.0 billion (down 61143608.93% YoY), while the FY2025 annual figure was -$452962.0, down 80.3% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$99657.0, up from -$6493.3 billion in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $2698.3 billion in Q3 2025, with the low at -$6493.3 billion in Q4 2025.
- The 5-year median for Net Income towards Common Stockholders is -$99657.0 (2026), against an average of -$345.0 billion.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders jumped 60.73% in 2022, then soared 460970719.11% in 2025.
- Grown Rogue International's Net Income towards Common Stockholders stood at -$422824.0 in 2022, then jumped by 259.03% to $672427.0 in 2023, then tumbled by 187.05% to -$585354.9 in 2024, then slumped by 1109293658.9% to -$6493.3 billion in 2025, then soared by 100.0% to -$99657.0 in 2026.
- Business Quant data shows GRUSF's Net Income towards Common Stockholders at -$99657.0 in Q1 2026, -$6493.3 billion in Q4 2025, and $2698.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Grown Rogue International | 109.32 Mn | 97.78 Mn | 5.37 Mn | -1.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.48 Mn |
| Mar 31, 2026 | -99,657.00 |
| Dec 31, 2025 | -6,493.31 Bn |
| Sep 30, 2025 | 2,698.31 Bn |
| Sep 30, 2024 | -585,354.88 |
| Jun 30, 2024 | -5.62 Mn |
| Dec 31, 2023 | 672,427.00 |
| Oct 31, 2023 | -1.56 Mn |
| Jul 31, 2023 | 205,190.44 |
| Apr 30, 2023 | 412,846.00 |
| Jan 31, 2023 | 931,945.00 |
| Jan 31, 2022 | -422,824.00 |
| Jul 31, 2021 | -54,533.00 |
| Apr 30, 2021 | -1.15 Mn |
| Jan 31, 2021 | -1.08 Mn |
| Oct 31, 2020 | 26,352.00 |
| Jul 31, 2020 | -798,200.00 |
| Apr 30, 2020 | -1.29 Mn |
| Jan 31, 2020 | -1.61 Mn |
| Oct 31, 2019 | -2.09 Mn |